Myocardial Delivery of SDF-1 in Patients with Ischemic Heart Disease: Safe and Promising
Heart Failure (HF) is a leading cause of mortality and morbidity in the US and its prevalence continues to increase especially as the population ages.1 A significant cause of heart failure is ischemic heart disease.1 Myocardial infarction and chronic ischemic disease can lead to the loss of a substantial number of cardiac myocytes thus justifying attempts to design an efficacious regenerative therapeutic strategy.2,3 Initial studies have documented the safety and feasibility of administrating stem or progenitor cells to restore the lost myocardium. Recently, intracoronary infusion of autologous c-kit+ cardiac stem cells in a Phase 1 trial resulted in significant clinical improvements in patients with ischemic cardiomyopathy.4,5 [Extract]
- Received January 28, 2013.
- Accepted January 30, 2013.
- Copyright © 2013, American Heart Association